title: Interpreting registry-derived drug studies: does societal context matter?
authors.forename: Joel M
authors.initials: JM
authors.lastname: Kremer
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Greenberg
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D019337:Hematologic Neoplasms / Q000453:epidemiology; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D012042:Registries; D012307:Risk Factors; D012720:Severity of Illness Index; D018855:Single-Payer System / Q000191:economics; D012878:Skin Neoplasms / Q000453:epidemiology; D012959:Socioeconomic Factors; D013548:Sweden / Q000453:epidemiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014481:United States
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D008727:Methotrexate